

July 12, 2016

For General Release

Information Services International-Dentsu, Ltd.

ISiD Commences Provision of “Endowment Application Web Service” for Pharmaceutical Industry

*Adopted for use by Kyowa Hakko Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation,
and Bayer Yakuhin, Ltd.*

Information Services International-Dentsu, Ltd. (Headquarters: Minato-ku, Tokyo; President: Setsuo Kamai; “ISiD”) has begun provision of the “Endowment Application Web Service,” the SasS-style cloud service for the pharmaceutical industry. This service contributes to the improved transparency with regard to the provision of funding from the pharmaceutical industry to research institutions. It is in use by three preceding users, Kyowa Hakko Kirin Co., Ltd. (Headquarters: Chiyoda-kyu, Tokyo; President: Nobuo Hanai), Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka-shi, Osaka-fu; President: Masayuki Mitsuka), and Bayer Yakuhin, Ltd. (Headquarters: Osaka-shi, Osaka-fu; President: Carsten Brunn), and is now beginning full-blown operation.

■Background■

Cooperation with research and medical institutions is essential to the development of new drugs in the pharmaceutical industry, and a diverse range of activities including basic research and clinical development are carried out based on a strong collaborative relationship. In such circumstances, monetary transactions occur in exchange for various activities, and a higher level of ethics is demanded for the pharmaceutical industry because it is connected to peoples’ lives and health. Thus it is an essential management issue for the pharmaceutical companies to ensure transparency and winning appreciation for their business activities. Accordingly, every company in the industry carries out information disclosure of the furnishing of funding of any sort based on the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions” (“Transparency Guidelines”) set down by the Japan Pharmaceuticals Manufacturers Association. Endowments as grants-in-aid and incentives for academic research are also subject to these guidelines.

To date, procedures related to the endowments have generally been carried out by the medical representatives of the pharmaceutical companies. Recently, there is an active trend for the pharmaceutical industry to seek research institutions or researchers as the recipients of these contributions publicly through websites.

■Characteristics of services■

The newly launched “Endowment Application Web Service” is performed safely and easily on the cloud. It covers the entire sequence of procedures, from the receipt of applications for endowment funds, the administration of screening results, and the management of research reports submission status. This is a shared service developed based on feedbacks regarding operational requirements from numerous users including the three preceding user companies. It is founded on the construction know-how of the “Transparency Guidelines Information Disclosure

Service,*” which has been utilized by 76 companies such as pharmaceutical companies and medical equipment manufacturers since ISID began offering the service in July 2013.

The main characteristics of this service are as follows:

1. Shared cloud service

The adjustments to authoring and storage of records are the important issues for the industry and the detailed policies may be set by Japan Pharmaceuticals Manufacturers Association.

ISID provides the service as a shared cloud service which enables improvements and additional functions, aggregating the Japan Pharmaceuticals Manufacturers Association principles and the operational needs from the pharmaceutical companies after the launch. Therefore, each company is able to use the service which is adapted to the latest requirements without individual investments for the updates

2. More efficient endowment application management

This service makes endowment application management more efficient significantly by provides functions that cover the sequence of operations regarding endowment application and issuing, such as acceptance of applications on the web, notification of screening results, and management of research report submission status, etc.

Major functions

- Acceptance of applications
- Status management for screening states
- Batch notification of screening results
- Notification for requests for research report submission
- Management of research report submission status
- Export of application information

3. Providing environments with high reliability and availability by utilizing Amazon Web Service (AWS)

For the system infrastructure of this service, ISID utilizes the AWS cloud service, which is provided to many businesses including financial institutions. ISID offers the service environment on AWS to ensure high availability and security in order to deal with researchers’ personal information and research content, etc.

URL: <http://www.isid.co.jp/solution/kifukinshinsei.html>

ISID contributes to strengthen the competitiveness of Japan’s pharmaceutical industry by expanding solutions for the life science industry.

* Transparency Guidelines Information Disclosure Service: An information disclosure service related to the provision of funding to medical institutions that ISID offers to the pharmaceutical industry and the medical equipment industry. This service is adopted by 76 companies as of May 2016, complying with the transparency guidelines of industry groups, such as the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions” by the Japan Pharmaceuticals Manufacturers Association, and those of the Japan Federation of Medical Devices Associations and the Japan Association of Clinical Reagents Industries.

URL: <http://www.isid.co.jp/solution/toumeisei.html>

Contact:

<For Business>
ISID Business Solutions Business Operations
TEL:+81 3-6713-6167
E-Mail: g-ls-info@group.isid.co.jp

<For Media>
ISID Corporate Communications Office
Kayoko Lee
TEL:+81 3-6713-6100
E-mail: g-pr@isid.co.jp

Note: Company and product names in this release are the trademark or registered trademark of each company respectively.